Novel macrocycles for the treatment of cancer diseases

1 . Compounds of the general formula (I):

wherein

R 1 is a C 1-6 alkyl, a C 2-6 alkynyl or a C 2-6 alkenyl radical,

R 2 is a hydrogen atom or a C 1-6 alkyl radical,

X—Y is selected from the following groups:

R 3 is a halogen atom or a C 1-6 alkyl, a C 2-6 alkenyl or a C 1-6 heteroalkyl radical,

R 4 is a bicycloaryl radical, a bicycloheteroaryl radical or a group of formula —C(R 5 )═CHR 6 ,

R 5 is a hydrogen atom or a methyl group and

R 6 is an optionally substituted aryl or heteroaryl group,

or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.

2 . Compounds of formula (I), wherein R 1 is a methyl group.

3 . Compounds according to claim 1 , wherein R 2 is a hydrogen atom or a methyl group.

4 . Compounds according to claim 1 , wherein R 3 is a methyl group, a trifluoromethyl group or a group of formula COOH.

5 . Compounds according to claim 1 , wherein R 3 is a trifluoromethyl group.

6 . Compounds according to claim 1 , wherein R 6 is an optionally substituted 5- or 6-membered heteroaryl radical having 1, 2 or 3 hetero atoms selected from S, N and O.

7 . Compounds according to claim 1 , wherein R 6 is an optionally substituted thiazole ring or pyridine ring.

8 . Compounds according to claim 1 , wherein R 4 is a group having the following formula:

9 . Pharmaceutical composition, which contains a compound according to claim 1 and optionally one or more carriers and/or one or more adjuvants.

10 . Use of a compound or a pharmaceutical composition according to claim 1 in the treatment of cancer diseases.